CASE.EDU:    HOME | DIRECTORIES | SEARCH
 
 
 

Email: courtney.bartel@case.edu

 

Courtney  A  Bartel

Entering Class: 2010
PhD Program: Pathology/Cancer Biology
Advisor: Mark Jackson, PhD

Undergraduate Institution: Vanderbilt University
Hometown: Mentor, OH.

Research Interests:

About me:

Comment about the MSTP program:

Featured Publication:

Bartel CA, Parameswaran N, Cipriano R, Jackson MW. FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. Oncotarget. 2016 May 21. doi: 10.18632/oncotarget.9544. [Epub ahead of print] PubMed PMID: 27221039.

Additional Publications:

Merry CR, McMahon S, Forrest ME, Bartels CF, Saiakhova A, Bartel CA, Scacheri PC, Thompson CL, Jackson MW, Harris LN, Khalil AM. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer. Oncotarget. 2016 Jul 16. doi: 10.18632/oncotarget.10637. [Epub ahead of print] PubMed PMID: 27449296.

Bartel CA, Parameswaran N, Cipriano R, Jackson MW. FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. Oncotarget. 2016 May 21. doi: 10.18632/oncotarget.9544. [Epub ahead of print] PubMed PMID: 27221039.

Cipriano R, Miskimen KL, Bryson BL, Foy CR, Bartel CA, Jackson MW. Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer. Mol Cancer Res. 2014 Aug;12(8):1156-65. doi: 10.1158/1541-7786.MCR-13-0289. Epub 2014 Apr 15. PubMed PMID: 24736947; PubMed Central PMCID: PMC4135001.

Cipriano R, Bryson BL, Miskimen KL, Bartel CA, Hernandez-Sanchez W, Bruntz RC, Scott SA, Lindsley CW, Brown HA, Jackson MW. Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B. Oncogene. 2014 Jun 19;33(25):3298-306. doi: 10.1038/onc.2013.293. Epub 2013 Aug 5. PubMed PMID: 23912460; PubMed Central PMCID: PMC3923847.

Cipriano R, Miskimen KL, Bryson BL, Foy CR, Bartel CA, Jackson MW. FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies. Oncotarget. 2013 May;4(5):729-38. PubMed PMID: 23676467; PubMed Central PMCID: PMC3742833.

Edit your page here.